Publications by authors named "William R Fairweather"

Doxofylline, an oral methylxanthine with bronchodilator and anti-inflammatory activities, offers a promising alternative to theophylline due to its superior efficacy/safety profile. No long-term studies on the efficacy and safety of doxofylline are currently available in asthma. The aim of the Long-term clinical trial on the Efficacy and Safety profile of Doxofylline in Asthma (LESDA) study was to investigate the safety and efficacy profile of doxofylline administered for one year in asthmatic patients.

View Article and Find Full Text PDF

This pooled analysis of double-blind, randomized, placebo-controlled trials aimed to investigate the impact of DOxofylline compaRed tO THEOphylline (DOROTHEO 1 and DOROTHEO 2 studies) on functional and clinical outcomes in asthma. Asthmatic patients ≥16 years of age with forced expiratory volume in 1 s (FEV) ≥50% and <80% and with ≥15% post-bronchodilator increase in FEV were randomized in a 1:1:1:1 ratio in DOROTHEO 1 to receive doxofylline 200 mg, doxofylline 400 mg, theophylline 250 mg, or placebo; in DOROTHEO 2 patients were randomized in a 1:1:1 ratio to receive doxofylline 400 mg, theophylline 250 mg, or placebo. All double-blind treatments were taken orally with immediate release formulations and three times daily.

View Article and Find Full Text PDF

Release data are often used improperly in stability studies by reproducing the same data and assigning it to each subset of a lot. The proper use of release data in stability studies is explored in this paper. The maximum likelihood solution is determined and compared with multiple imputation and one ad hoc procedure.

View Article and Find Full Text PDF

Discrepancies in the data of a bioequivalence study led to questions about the procedures used in the analytical laboratory. In this article we describe some statistical and graphical procedures that were used to explore the causes of a process failure for an unvalidated process.

View Article and Find Full Text PDF

When marketed lots of pharmaceutical products produce a number of out-of-specification (OOS) samples, it can be very disruptive. In some cases such lots must be recalled, at substantial expense. We present a model of the probability of OOS samples and show quantitatively how this probability depends on the underlying variation and on the original stability study.

View Article and Find Full Text PDF

Postmarketing stability studies of vaccines that tend to be close to their clinical specification at the end of the expiration dating period may require enhanced annual monitoring. In addition, an early assessment of product stability prior to completion of each individual study is desired. However, predictive measures of individual lots may produce early indication of failure.

View Article and Find Full Text PDF